Advancing Cancer Treatment Through Research & Innovation
Our research focuses on developing breakthrough treatments that combine cutting-edge science with personalized patient care, pushing the boundaries of what's possible in cancer treatment.
Current Research Projects
Our current research projects are focused on developing breakthrough treatments that combine cutting-edge science with personalized patient care, pushing the boundaries of what's possible in cancer treatment.
Efficacy of Compression Therapy for Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients with Early Breast Cancer: Insights from a Single-Centre Experience in Bangladesh
Prospective
Research Objectives:
- • Incidence of CTCAE version 5 grade 2 or higher CIPN in both upper and lower extremities during entire period of chemotherapy.
The Efficacy of Pembrolizumab for Treatment of Early Triple Negative Breast Cancer: A Single-center, Open, Randomized Controlled Trial
Primary endpoints: A) Pathological Complete Response at the time of definitive surgery B) Event-free survival in the intention-to-treat population Secondary endpoints: Overall survival at the end of 15 months
Research Objectives:
- • A prospective study to measure the efficacy of Pembrolizumab in Early Triple Negative Breast Cancer (TNBC) patients of Bangladeshi population.
Recent Publications
Peer-reviewed research contributions published in leading oncology journals, advancing the field of cancer treatment.
Randomized Clinical Trial on Three Different Platinum Based Chemotherapy in Advanced NSCLC in Bangladeshi Population
This Randomized Clinical Trial (RCT) was carried out in the Department of Medical Oncology at National Institute of Cancer Research and Hospital (NICRH), Mohakhali, Dhaka. Patients were enrolled from January …
Key Findings:
Significant G-1/2 Hb% was found in Day7 in TP (16.67%) and EP (10.52%) arm and in 6 months EP (31.58%) and TP (29.17%). WBC G-1/2 …
Primary Jejunal Gastrointestinal Stromal Tumor: Diagnosis Delay of 3 Years but Successful Management in Early Stage (II) by Surgery and Adjuvant Therapy
In the digestive system, mesenchymal origin of tumors is quite rare; in general, they are recognized as gastrointestinal stromal tumors (GISTs). The incidence of GISTs is very low (2 in …
Key Findings:
We present the case of a 62-year-old Bangladeshi female with a history of GI bleeding 3 years earlier; the cause of the bleeding had not …
Sister Mary Jospeh's nodule as initial presentation of carcinoma caecum-case report and literature review
Umbilical metastases [Sister Mary Joseph's nodules (SMJN)] are relatively rare and are associated usually with advanced intra-abdominal tumors from the gastrointestinal tract (GIT) or from the gynecological malignancies and they …
Key Findings:
Umbilical metastases [Sister Mary Joseph's nodules (SMJN)] are relatively rare and are associated usually with advanced intra-abdominal tumors from the gastrointestinal tract (GIT) or from …
Showing 16 to 18 of 19 publications
Conference Presentations & Speaking Engagements
Sharing research findings and clinical insights at leading medical conferences worldwide.
ESMO Asia 2025
Clinicopathological pathological characteristics in young breast cancer patient
A single center retrospectives study in a low and middle income country
KSMO 2025
Survival Analysis of CNS patients in Bangladesh – focusing the multidisciplinary approaches among 149 patients in a single centre retrospective analysis from 2018- 2023.
Introduction: Central Nervous Tumor (CNS) tumor is variable survival status due to its location and age groups. We tried to find selected CNS tumors among adult and child with tri-modalities treatment and compared the survival and prognostic factors among 149 patients first time in Bangladesh. Methods: Retrospective analysis was done through hospital information system among CNS tumors patient’s prescription from 2018 to 2023. Follow up was also confirmed through tele conversation where the last follow up was not recent. A model with python created to analyze the survival in different groups with log rank test and COX proportional hazard ratio also tested.
Showing 5 to 6 of 6 presentations